— Know what they know.
Not Investment Advice

NATCOPHARM.NS NSE

Natco Pharma Limited
1W: -1.7% 1M: -3.3% 3M: -11.8% YTD: -2.9% 1Y: -9.0% 3Y: -6.2% 5Y: -13.2%
₹819.00 ($8.50)
-8.50 (-1.03%)
 
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 35 · ₹146.7B mcap · 84M float · 0.756% daily turnover
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap₹146.7B ($1.5B)
52W Range752.5-1226.8
Volume717,250
Avg Volume632,526
Beta0.16
Dividend₹4.49
Analyst Ratings
No analyst coverage
Company Info
CEORajeev Nannapaneni
Employees4,433
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date1996-01-01
Natco House
Hyderabad, TS 500034
IN
91 40 2354 7532
About Natco Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms